Protective Role of Ethanol Extract of Cibotium barometz (Cibotium Rhizome) against Dexamethasone-Induced Muscle Atrophy in C2C12 Myotubes

by Selleckchem | Feb 14 2024

Sarcopenia is a progressive muscle disease characterized by the loss of skeletal muscle mass, strength, function, and physical performance. Since the disease code was assigned, attention has been focused on natural products that can protect against muscle atrophy. Cibotium barometz (Cibotium Rhizome) has been used as an herbal medicine for the treatment of bone or joint diseases in Asian countries. However, no studies have identified the mechanism of action of Cibotium Rhizome on muscle atrophy related to sarcopenia at the site of myotubes. The aim of this study was to investigate the improvement effect of the ethanol extract of Cibotium Rhizome (ECR) on dexamethasone-induced muscle atrophy in an in vitro cell model, i.e., the C2C12 myotubes. High-performance liquid chromatography was performed to examine the phytochemicals in ECR. Seven peaks in the ECR were identified, corresponding to the following compounds: protocatechuic acid, (+)-catechin hydrate, p-coumaric acid, ellagic acid, chlorogenic acid, caffeic acid, and ferulic acid. In atrophy-like conditions induced by 100 μM dexamethasone for 24 h in C2C12, ECR increased the expression of the myosin heavy chain, p-Akt, the p-mammalian target of rapamycin (mTOR), p-p70S6K, and repressed the expression of regulated in development and DNA damage responses 1 (REDD1), kruppel-like factor 15 (KLF 15), muscle atrophy F-box, and muscle-specific RING finger protein-1 in C2C12. In addition, ECR alleviated dexamethasone-induced muscle atrophy by repressing REDD1 and KLF15 transcription in C2C12 myotubes, indicating the need for further studies to provide a scientific basis for the development of useful therapeutic agents using ECR to alleviate the effects of skeletal muscle atrophy or sarcopenia.

Comments:

That's an intriguing study! It appears the researchers investigated the effects of Cibotium Rhizome extract (ECR) on dexamethasone-induced muscle atrophy using C2C12 myotubes as an in vitro model. They identified several compounds in the extract through high-performance liquid chromatography and observed positive impacts on various markers related to muscle atrophy.

The study highlights the potential of ECR in mitigating muscle atrophy induced by dexamethasone by influencing the expression of various proteins involved in muscle growth and atrophy pathways. Some notable findings include increased expression of myosin heavy chain, p-Akt, p-mTOR, and p-p70S6K, as well as the repression of proteins associated with muscle atrophy like REDD1, KLF15, muscle atrophy F-box, and muscle-specific RING finger protein-1 in the C2C12 myotubes.

The results indicate a promising avenue for further research on ECR as a potential therapeutic agent to combat skeletal muscle atrophy or sarcopenia. Understanding the mechanisms of action and conducting additional studies could pave the way for the development of novel treatments or interventions using Cibotium Rhizome extract to counteract muscle-related conditions.

It's exciting to see natural products being investigated for their potential in addressing muscle-related diseases. These findings could eventually contribute to the development of therapies aimed at alleviating the effects of sarcopenia or other conditions related to muscle atrophy.